Predictors for early readmission in patients hospitalized with new onset pediatric lupus nephritis

Abstract

Objective

The objective is to determine the 30-day hospital readmission rate following a hospitalization due to pediatric lupus nephritis of recent onset and characterize the risk factors associated with these early readmissions.

Methods

The study included 76 children hospitalized from 01/01/2008 to 4/30/2017 due to a new diagnosis of lupus nephritis. We calculated the 30-day hospital readmission rate and compared the characteristics of the patients that were readmitted to patients that were not readmitted using univariable and multivariable analysis.

Results

The 30-day readmission rate was 17.1%. Factors that predicted hospital readmission in unavailable analysis were male gender (38.5 vs 14.3%, p = 0.04), not receiving pulse steroids (30.8 vs 3.2%, p = < .001), receiving diuretic treatment (69.2 vs 34.9%, p = .02), receiving albumin infusions (46.2 vs 12.7%, p = .004), stage 2 hypertension on day one of admission (76.9 vs 41.3%, p = .02), a higher white blood cell count on discharge (13.7 × 10³/mm³ vs 8.8 × 10³/mm3^, p = .023), need for non-angiotensin converting enzyme (ACE) antihypertensive drugs (76.9 vs 46%, p = .042), and being discharged on nonsteroidal anti-inflammatory drugs (NSAIDs) (23.1 vs 4.8%, p = .025). Multivariable analysis demonstrated an increased risk of readmission for patients not treated with intravenous pulse methylprednisolone (IVMP) (OR = 17.5 (1.81–168.32) p = .013), and for those who required intravenous albumin assisted diuresis for hypervolemia (OR=6.25 (1.29–30.30) p = .022).

Conclusion

In all, 17% of children hospitalized due to new onset lupus nephritis were readmitted within 30 days of discharge. Absence of IVMP and receiving intravenous albumin assisted diuresis during initial hospitalization increase the risk of early readmission in new onset pediatric lupus nephritis.

Keywords

Pediatric lupus pediatric lupus nephritis pediatric lupus readmissions

Get full access to this article

View all access options for this article.

References

Malleson

Fung

Rosenberg

. The incidence of pediatric rheumatic diseases: Results from the Canadian pediatric rheumatology association disease registry. J Rheumatol 1996; 23: 1981–1987.

Pineles

Valente

Warren

, et al. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 2011; 20: 1187–1192.

Lim

Helmick

Gordon

, et al. The georgia lupus registry: A population-based estimate of the incidence and prevalence of childhood-onset SLE. In: The American College of Rheumatology and Association of Rheumatology Health Professionals Annual Scientific Meeting 2009, Philadelphia, Pennsylvania, 16–21 October 2009, abstract no. 125922009.

Kurahara

Tokuda

Grandinetti

, et al. Ethnic differences in risk for pediatric rheumatic illness in a culturally diverse population. J Rheumatol 2002; 29: 379–383.

Houghton

Page

Cabral

, et al. Systemic lupus erythematosus in the pediatric North American native population of British Columbia. J Rheumatol 2006; 33: 161–163.

Sinha

Raut

. Pediatric lupus nephritis: Management update. World J Nephrol 2014; 3: 16–23.

Hiraki

Benseler

Tyrrell

, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: A longitudinal study. J Pediatr 2008; 152: 550–556.

Batinic

Milosevic

Coric

, et al. Lupus nephritis in Croatian children: Clinicopathologic findings and outcome. Lupus 2015; 24: 307–314.

Knight

Weiss

Morales

, et al. National trends in pediatric systemic lupus erythematosus hospitalization in the United States: 2000–2009. J Rheumatol 2014; 41: 539–546.

10.

Yazdany

Marafino

Dean

, et al. Thirty-day hospital readmissions in systemic lupus erythematosus: Predictors and hospital- and state-level variation. Arthritis Rheumatol 2014; 66: 2828–2836.

11.

Tan

Cohen

Fries

, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

12.

Hochberg

. Updating the American college of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

13.

Weening

D’Agati

Schwartz

, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241–250.

14.

Gladman

Ibañez

Urowitz

. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.

15.

Falkner

Daniels

. National high blood pressure education program working group on high blood pressure in C, adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555–576.

16.

Liang

Corzilliius

Bae

, et al. The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608.

17.

Petri

Orbai

Alarcón

, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

18.

Markham

Hall

Gay

, et al. Length of Stay and Cost of Pediatric Readmissions. Pediatrics 2018; 141: e20172934.

19.

Sobota

Graham

Neufeld

, et al. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children’s hospitals: Risk factors and hospital variation. Pediatr Blood Cancer 2012; 58: 61–65.

20.

Barnes

Kochar

Long

, et al. The burden of hospital readmissions among pediatric patients with inflammatory bowel disease. J Pediatr 2017; 191: 184–189.

21.

Slone

Rai

Ahmad

, et al. Risk factors for readmission after initial diagnosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 51: 375–379.

22.

Edwards

Snaith

Isenberg

. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis 1987; 46: 773–776.

23.

Liebling

McLaughlin

Boonsue

, et al. Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 1982; 9: 543–548.

24.

Tanaka

Tateyama

Waga

. Methylprednisolone pulse therapy in Japanese children with severe lupus nephritis. Pediatr Nephrol 2001; 16: 817–819.

25.

Bertoni

Brugnolo

Bertoni

, et al. Long term efficacy of high-dose intravenous Methylprednisolone pulses in active lupus Nnphritis: A 21 month prospective study. Scand J Rheumatol 1994; 23: 82–86.

26.

Rianthavorn

Buddhasri

. Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis. Pediatr Nephrol 2015; 30: 1969–1976.

27.

Vachvanichsanong

Dissaneewate

McNeil

. Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood-onset lupus nephritis: A 23-year experience in a single centre. Nephrol Dial Transplant 2009; 24: 2729–2734.

28.

Murphy

Isenberg

. Effect of gender on clinical presentation in systemic lupus erythematosus. Rheumatology 2013; 52: 2108–2115.

29.

Hagelberg

Lee

Bargman

, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002; 29: 2635–2642.

30.

Ntatsaki

Isenberg

. Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. Expert Rev Clin Immunol 2015; 11: 837–848.

31.

Hanly

O’Keeffe

, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford) 2016; 55: 252–262.

32.

USCB . New Census Bureau Population Estimates Show Dallas-Fort Worth-Arlington Has Largest Growth in the United States 2018, https://www.census.gov/newsroom/press-releases/2018/popest-metro-county.html#popest-tab6 (2018, accessed 5 January 2018).

33.

USCB . Patterns of Metropolitan and Micropolitan Population Change: 2000–2010, https://www.census.gov/library/publications/2012/dec/c2010sr-01.html (2012, accessed 5 January 2018).